Solebury Trout KOL Day
We are pleased to host our first Solebury Trout KOL Day in New York on November 15, 2019, partnered with White & Case
White & Case event Space in NYC
1221 6th Ave, New York, NY 10020
Attending companies and KOLs:
NeuroRx (Private) – 8 AM
Topic: Clinical Insights of New Rapidly Acting, NMDA-based Antidepressants
KOL Participant: Daniel Javitt, MD – Columbia University Irving Medical School
Dr. Javitt's research focuses on brain mechanisms of psychosis and other severe psychiatric disorders, with special emphasis on the role of brain glutamate systems and N-methyl-D-aspartate (NMDA)-type glutamate receptors in health and disease. Dr. Javitt was among the first to demonstrate a link between NMDA dysfunction and schizophrenia, and has been instrumental in developing glutamatergic theories of schizophrenia over the past 20 years. He was also among the first to test new classes of NMDA-based treatments for schizophrenia, including glycine, D-serine and glycine transport inhibitors, and has more recently initiated studies of NMDA receptor antagonists, such as ketamine and high-dose D-cycloserine in treatment of depression, and of brain stimulation methods, including transcranial direct current stimulation (tDCS) as an adjunct to cognitive remediation.
Kiadis (KDS-AMS) – 9:30AM
Topic: Targeting hematological malignancies w proprietary & synergistic NK-cell (CSTD002) and T-cell (ATIR101) platforms administered as adjunctive I-O on top of HSCT.
KOL Participant: Dean Lee, MD, PhD – Hematology and Oncology at Nationwide Children’s Hospital, director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children's Hospital, The Ohio State University Comprehensive Cancer Center
Dr Lee is a physician in the Division of Hematology and Oncology at Nationwide Children’s Hospital and director of the Cellular Therapy and Cancer Immunology Program at Nationwide Children's Hospital and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He is a professor of pediatrics at The Ohio State University College of Medicine and the DiMarco Family Endowed Chair in Cell Based Therapy. Dr Lee is chair of the Cellular Therapy Strategy Group for the Pediatric Blood and Marrow Transplant Consortium, member of the NIH Recombinant DNA Advisory Committee, and member of the Cell Therapy Steering Committee for the Children’s Oncology Group. Dr Lee earned his bachelor’s degree in natural sciences from Fresno Pacific College, completed his medical, doctoral, and pediatric residency training at Loma Linda University then completed a fellowship in pediatric hematology/oncology at Texas Children’s Hospital, Baylor College of Medicine.
Lineage (LCTX) – 11AM
Topic: Three clinical-stage cell therapy programs in dry age-related macular degeneration, spinal cord injury, and oncology
KOL Participant: Allen Ho, MD, FACS - Wills Eye Hospital Attending Surgeon and Director of Retina Research, Professor of Ophthalmology, Thomas Jefferson University
Dr. Ho maintains special interests in macular diseases, diabetic retinopathy, surgical retinal diseases and clinical trials investigating new treatments for vitreoretinal diseases including gene and cell therapies and new surgical drug delivery devices and techniques. His experience includes collaborative translational and clinical trial clinical research with expertise in study design, methodological testing, data analyses, surgical instrumentation and procedure development, execution and communication of these studies and their study results. He is the current President of The Retina Society and serves on its Executive Committee.
KOL Participant: John Steeves, BSc, PhD - Emeritus Principal Investigator, ICORD, Professor, Department of Neuroscience, University of British Columbia
John Steeves, B.Sc., Ph.D., is currently a Professor in the Department of Neuroscience at the University of British Columbia and a Principal Investigator and Founding Director of ICORD (International Collaboration On Repair Discoveries), an interdisciplinary research centre focused on spinal cord injury. He is the Chair of SCOPE (Spinal Cord Outcomes Partnership Endeavor), which works on translating discoveries to clinical trials. Dr. Steeves obtained his B.Sc. and Ph.D. at the University of Manitoba and completed his Post-Doctoral Fellowship at the University of Alberta. After a long career in basic science research, Dr. Steeves has turned his attention to translational research, making application of research to patients a higher priority. His current research focuses on arm and hand rehabilitation after spinal cord injuries. His goal is to improve rehabilitation strategies by using assistive robots and virtual-reality training. With a number of colleagues from across the globe, Dr. Steeves also works on developing better criteria for enrolling participants in SCI clinical trials, and on improving outcome measures of the electrical properties of the body and the nervous system. Better measurements of the outcomes of clinical trials can establish how well they help people with SCI, and therefore promote better recovery. Dr. Steeves also collaborates with EMSCI (European Multicenter Study about Spinal Cord Injury) to analyze the database on SCI patients and their injuries to determine better clinical trial protocols.
PharmaMar (PHM:ES) – 12:30 PM
Topic: SCLC: Recent approvals in first and third line could be joined with Lurbinectedin in 2nd line
KOL Participant: Dr Jacob Sands - Dana-Faber Cancer Institute
Dr Sands is a thoracic medical oncologist at Dana-Farber Cancer Institute and an instructor of medicine at Harvard Medical School. In addition, he is a National Spokesperson for the American Lung Association and is a current member of the NCCN Small Cell Lung Cancer panel.
Dr. Sands received his MD from the University of Cincinnati in 2005. He completed his residency in internal medicine at the University of California, Davis and fellowship training in hematology/oncology also at the University of California, Davis. He joined the faculty in the Lowe Center for Thoracic Oncology at Dana-Farber in 2017. His research focuses on improved diagnostics and treatments for small cell lung cancer as well as improving lung screening and assisting in the development of lung screening programs throughout the country.
His research focuses on the diagnostics and treatment of small cell lung cancer with ongoing development of new treatment protocols for clinical trials. Dr. Sands is also active in advancing lung screening as a way of diagnosing lung cancer early enough to significantly increase the chances of cure. He is the treasurer of the Rescue Lung Rescue Life Society, an organization focused on assisting hospitals with building robust lung screening programs.
Targovax (TRVX:OS) – 2:00PM
Topic: Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications
KOL Participant: Alexander N. Shoushtari, MD, Medical Oncologist, Memorial Sloan Kettering
Dr. Shoushtari’s is a renowned expert in melanoma, with a research focus on uveal and mucosal melanomas. He has been part of several immunotherapy trials at MSKCC, and is the Principal Investigator on the ONCOS-102 phase I trial in CPI refractory advanced melanoma. Dr. Shoushtari is a member of the research team of Dr. Jedd Wolchok, MD, PhD, Chief, Melanoma and Immunotherapeutics Service at the Memorial Sloan Kettering Cancer Center.
Angiocrine (Private) – 3:30PM
Topic: E-CEL® (Engineered Endothelial Cell) Therapy and Vascular Niche Biology
KOL Participant: Shahin Rafii - Weill Cornell Medicine
Shahin Rafii's laboratory focuses on stem cell biology and angiogenesis uses in vivo mouse model and mouse and human genetics, tissue culture approaches and molecular biology to model angiognesis, cancer and stem cell metabolic regulation. Genetic, genomic, molecular and cell biological techniques are combined to achieve a systems level understanding of these complex processes.
Currently, Rafii's work is focused on identifying the molecular and cellular pathways involved in organ regeneration and tumor growth. He has established the concept that vascular endothelial cells are not just inert plumbing to deliver oxygen and nutrients, but also by production of tissue-specific growth factors, defined as angiocrine factors, support organ regeneration and tumor proliferation. He has shown that bone marrow endothelial cells by elaboration of angiocrine factors, such as Notch ligands, support stem cell self-renewal and differentiation into lymphoid and myeloid progenitors. He has recently demonstrated that liver and lung endothelial cells are endowed with unique phenotypic and functional attributes and by production of unique instructive growth factors contribute to the hepatic and alveolar regeneration.
Location of the Event and Other Places